Targeted gene delivery of BMPR2 attenuates pulmonary hypertension

European Respiratory Journal

Volumn 39, Issue 2, 2012, Pages 329-343

  Reynolds, A M ^a,b   Holmes, M D ^a,b,c   Danilov, S M ^d   Reynolds, P N ^a,b,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b HANSON INSTITUTE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Endothelial to mesenchymal transition; Gene therapy; Hypoxia; Monocrotaline; Vascular remodelling

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CYCLINE; FIBRONECTIN; KI 67 ANTIGEN; MONOCROTALINE; PROTEIN S 100; PROTEIN S 100A; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2 GENE; CELL ADHESION; CELL ELONGATION; CELL PROLIFERATION; CELL SHAPE; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CHRONIC HYPOXIA; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE; GENE EXPRESSION; HEART FUNCTION; HEART INDEX; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; IN VITRO STUDY; INTRACELLULAR SIGNALING; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR ENDOTHELIUM; RAT; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR MUSCULARISATION; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANOXIA; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL DIVISION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; HYPERTENSION, PULMONARY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TRANSGENES; UP-REGULATION;

EID: 84856721781     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00187310     Document Type: Article

References (51)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
2. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S55-S66.
3. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744. (Pubitemid 30659603)
4. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26: 81-84.
5. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S32-S42.
6. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-1678. (Pubitemid 34298611)
7. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249. (Pubitemid 40246523)
8. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
9. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
10. McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Circulation 2010; 122: 106-108.
11. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1013-L1032.
12. Takahashi H, Goto N, Kojima Y, et al. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 290: L450-L458. (Pubitemid 43725089)
13. Morty RE, Nejman B, Kwapiszewska G, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscl Thromb Vasc Biol 2007; 27: 1072-1078. (Pubitemid 46641959)
14. Reynolds AM, Xia W, Holmes MD, et al. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1182-L1192. (Pubitemid 47084862)
15. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling crosstalk. Cytokine Growth Factor Rev 2005; 16: 251-263. (Pubitemid 40910315)
16. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99: 675-691. (Pubitemid 44498302)
17. Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009; 119: 566-576.
18. Danilov SM, Gavrilyuk VD, Franke FE, et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1335-L1347.
19. Metzger R, Franke FE, Bohle RM, et al.Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity. Microvascular Res 2011; 81: 206-215.
20. Reynolds PN, Zinn KR, Gavrilyuk VD, et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2000; 2: 562-578.
21. Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838-842. (Pubitemid 32816753)
22. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-961. (Pubitemid 47222040)
23. West J, Fagan K, Steudel W, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004; 94: 1109-1114. (Pubitemid 38579706)
24. West J, Harral J, Lane K, et al. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008; 295: L744-L755.
25. Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation 2001; 104: 790-795. (Pubitemid 32762677)
26. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiformlesions in primary pulmonary hypertension. Circ Res 2001; 88: 2e-11e.
27. Thomas M, Docx C, Holmes AM, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol 2009; 174: 380-389.
28. Zakrzewicz A, Kouri FM, Nejman B, et al. The transforming growth factor b/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension. Eur Respir J 2007; 29: 1094-1104. (Pubitemid 46895367)
29. Burke DL, Frid MG, Kunrath CL, et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 2009; 297: L238-L250.
30. Masri FA, Xu W, Comhair SA, et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L548-L554. (Pubitemid 47358814)
31. Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev 2000; 11: 5-13. (Pubitemid 30169721)
32. Upton PD, Morrell NW. TGF-b and BMPR-II pharmacology - implications for pulmonary vascular diseases. Curr Opin Pharmacol 2009; 9: 274-280.
33. Lee NY, Ray B, How T, et al. Endoglin promotes transforming growth factor β-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 2008; 283: 32527-32533.
34. Tian F, Zhou AX, Smits AM, et al. Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun 2010; 392: 283-288.
35. Hassel S, Schmitt S, Hartung A, et al. Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg 2003; 85: 44-51. (Pubitemid 36951116)
36. Nohe A, Keating E, Underhill TM, et al. Effect of the distribution and clustering of the type I A BMP receptor (ALK3) with the type II BMP receptor on the activation of signalling pathways. J Cell Sci 2003; 116: 3277-3284. (Pubitemid 37038976)
37. Takahashi K, Kogaki S, Matsushita T, et al. Hypoxia induces alteration of bone morphogenetic protein receptor signaling in pulmonary artery endothelial cell. Paediatric Res 2007; 61: 392-397. (Pubitemid 46569289)
38. McMurtry MS, Moudgil R, Hashimoto K, et al. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 292: L872-L878. (Pubitemid 46608233)
39. Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: L525-L534. (Pubitemid 47358808)
40. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002; 90: 1189-1196. (Pubitemid 34786904)
41. Zhu P, Huang L, Ge X, et al. Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling. Int J Exp Path 2006; 87: 463-474. (Pubitemid 44813865)
42. Kitao A, Sato Y, Sawada-Kitamura S, et al. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol 2009; 175: 616-626.
43. Arciniegas E, Sutton AB, Allen TD, et al. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci 1992; 103: 521-529.
44. Arciniegas E, Frid MG, Douglas IS, et al. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1-L8. (Pubitemid 47080705)
45. Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2010; 43: 629-634.
46. Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res 2009; 10: 95.
47. Izumi M, Kawakami Y, Glasgow JN, et al. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J Gene Med 2005; 7: 1517-1525. (Pubitemid 43025512)
48. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441: 239-243.
49. Brunetti-Pierri N, Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 2008; 15: 553-560.
50. Jurasz P, Courtman D, Babaie S, et al. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol Ther 2010; 126: 1-8.
51. Sobolewski A, Rudarakanchana N, Upton PD, et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet 2008; 17: 3180-3190.